Genetics, genomics and proteomics
Cintia De Paiva, MD, PhD
Baylor College of Medicine
Houston, TX, United States
Disclosure(s): Aerie Pharmaceuticals: Grant/Research Support (Terminated, December 31, 2022); BioAegis: Grant/Research Support (Terminated, December 31, 2022); Roche: Grant/Research Support (Terminated, May 31, 2022); Serpass Biologicals: Grant/Research Support (Ongoing); Spring Discovery: Consultant (Terminated, August 31, 2022)
Christopher Lessard, PhD
Oklahoma Medical Research Foundation
Oklahoma City, OK, United States
Disclosure(s): Janssen: Grant/Research Support (Ongoing)
Dr. Blake M. Warner, PhD, MPH, DDS
National Institutes of Health
Bethesda, MD, United States
Disclosure(s): Astellas Pharma, Inc.: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing)
Progress in developing effective therapies for Sjögren’s syndrome has been hampered by an incomplete understanding of molecular and cellular pathophysiology in both blood and affected tissues and how this relates to heterogeneity of clinical expression. Advances in genomic, proteomic, and cellular technologies are expanding the identification of disease-associated cell types that explain clinical and molecular heterogeneity, providing new insights to guide drug development.
Speaker: Christopher Lessard, PhD – Oklahoma Medical Research Foundation
Speaker: Dr. Blake M. Warner, PhD, MPH, DDS – National Institutes of Health
Speaker: Cintia S. De Paiva, MD, PhD – Baylor College of Medicine